loading page

Inactivation of SERCA2 Cys674 accelerates aortic aneurysms by suppressing PPARγ
  • +3
  • Yumei Que,
  • Xi Shu,
  • Langtao Wang,
  • Sai Wang,
  • Pingping Hu,
  • Xiaoyong Tong
Yumei Que
Innovative Drug Research Center
Author Profile
Xi Shu
Innovative Drug Research Center
Author Profile
Langtao Wang
Innovative Drug Research Center
Author Profile
Sai Wang
Innovative Drug Research Center
Author Profile
Pingping Hu
Innovative Drug Research Center
Author Profile
Xiaoyong Tong
Innovative Drug Research Center
Author Profile


Background and Purpose Inactivation of Cys674 (C674) in the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 (SERCA2) by causing the accumulation of intracellular Ca2+ to activate calcineurin-mediated nuclear factor of activated T-lymphocytes (NFAT)/NF-κB pathways, resulted in the phenotypic modulation of smooth muscle cells (SMCs) to accelerate angiotensin II-induced aortic aneurysm. Our goal was to investigate the mechanism involved. Experimental Approach We used heterozygous SERCA2 C674S knock-in (SKI) mice, where half of C674 was substituted by serine, to represent partial irreversible oxidation of C674. The aortas of SKI mice and their littermate wild-type mice were collected for RNA sequencing, cell culture, protein expression, luciferase activity and aortic aneurysm analysis. KEY RESULTS Inactivation of C674 inhibited the promoter activity and protein expression of PPARγ, which could be reversed by inhibitors of calcineurin or NF-κB. Overexpression of PPARγ2 inhibited the phenotypic modulation of SKI SMCs. Pioglitazone, the activator of PPARγ, blocked the activation of NFAT/NF-κB, inhibited SMC phenotypic modulation, and ameliorated angiotensin II-induced aortic aneurysms in SKI mice. CONCLUSIONS AND IMPLICATIONS The inactivation of SERCA2 C674 promotes the development of aortic aneurysm by disrupting the balance between PPARγ and NFAT/NF-κB. Our study highlights the importance of C674 redox status in regulating PPARγ to maintain aortic homeostasis.

Peer review status:ACCEPTED

26 Aug 2020Submitted to British Journal of Pharmacology
26 Aug 2020Submission Checks Completed
26 Aug 2020Assigned to Editor
10 Sep 2020Reviewer(s) Assigned
29 Sep 2020Review(s) Completed, Editorial Evaluation Pending
30 Sep 2020Editorial Decision: Revise Minor
24 Dec 20201st Revision Received
24 Dec 2020Submission Checks Completed
24 Dec 2020Assigned to Editor
04 Jan 2021Reviewer(s) Assigned
04 Feb 2021Review(s) Completed, Editorial Evaluation Pending
04 Feb 2021Editorial Decision: Accept